NCT01348919View on ClinicalTrials.gov

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 3, 2011

Primary Completion Date

March 14, 2013

Study Completion Date

March 14, 2013

Conditions
Multiple Myeloma
Interventions
DRUG

CEP-18770

CEP-18770 will be administered per dose and schedule specified in the arm description.

DRUG

Lenalidomide

Lenalidomide will be administered per dose and schedule specified in the arm description.

DRUG

Dexamethasone

Dexamethasone will be administered per dose and schedule specified in the arm description.

Trial Locations (8)

1640

Teva Investigational Site 201, Auckland

3204

Teva Investigational Site 206, Hamilton

6021

Teva Investigational Site 205, Newtown

8011

Teva Investigational Site 200, Christchurch

30912

Teva Investigational Site 1, Augusta

40536

Teva Investigational Site 3, Lexington

77030

Teva Investigational Site 2, Houston

92024

Teva Investigational Site 204, Auckland

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT01348919 - Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter